Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephane Doucet

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Nature Reviews. Clinical Oncology|April 18, 2013
Haematological cancer: Indolent lymphoma--why not to sprint at the start of a marathonStephane Doucet, Leo I Gordon
Current Treatment Options in Oncology|March 5, 2013
Primary central nervous system lymphomaStephane Doucet, Priya Kumthekar, Jeffrey Raizer
Leukemia Research Reports|February 9, 2026
Gemcitabine, dexamethasone and cisplatin with or without rituximab is highly effective as a mobilization regimen in relapsed or refractory lymphomaVincent T Taillefer, Marianne Emond, Marie-Hélène Leblanc, et al.
British Journal of Haematology|September 13, 2024
A randomized trial of ibrutinib and R-GDP prior to stem cell transplant in relapsed diffuse large B-cell lymphomaJohn Kuruvilla, Christopher Rushton, Diego Villa, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Nature Reviews. Clinical Oncology|April 18, 2013
Haematological cancer: Indolent lymphoma--why not to sprint at the start of a marathonStephane Doucet, Leo I Gordon
Current Treatment Options in Oncology|March 5, 2013
Primary central nervous system lymphomaStephane Doucet, Priya Kumthekar, Jeffrey Raizer
Leukemia Research Reports|February 9, 2026
Gemcitabine, dexamethasone and cisplatin with or without rituximab is highly effective as a mobilization regimen in relapsed or refractory lymphomaVincent T Taillefer, Marianne Emond, Marie-Hélène Leblanc, et al.
British Journal of Haematology|September 13, 2024
A randomized trial of ibrutinib and R-GDP prior to stem cell transplant in relapsed diffuse large B-cell lymphomaJohn Kuruvilla, Christopher Rushton, Diego Villa, et al.
Pageof 1